Leállítva4. fázis
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
A legfontosabb adatok
- Ki végzi
- Messoud Ashina, MD
- Hol
- Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 4. fázis
- Résztvevők
- 8 fő vett részt
- Kezdés
- 2022. jún. 30.
- Befejezés
- 2024. ápr. 15.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Almotriptan 12.5 Mg Oral Tablet
- Ubrogepant 50Mg Tab
- A regiszteradat frissítve
- 2025. május 31.
- Miért állt le
- Issues with recruitment
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Subject has provided informed consent prior to initiation of any study-specific activities/procedures
- Aged 18 to 65 years upon entry into screening
- History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the ICHD-3 criteria based on medical records and/or patient self-report
- Not more than 12 attacks per month with moderate to severe headache pain in each of the previous 3 months
Ki nem vehet részt
- Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per months in the previous 3 months
- Required hospital treatment of a migraine attack 3 or more times in the previous 6 months; Other Medical Conditions
- Has a history of any prior gastrointestinal conditions (e.g., diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of investigational product; participants with prior gastric bariatric interventions which have been reversed are not excluded
- Current treatment with monoclonal antibodies targeting calcitonin gene related piptide (CGRP) or CGRP receptors, or current use of small-molecule CGRP receptor antagonist (e.g. erenumab, fremanezumab, galcaneszumab or atogeptant)
- Changes in treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin norepinephrine reuptake inhibitors (SNRI) within the last two months
- Use of the following medication within 30 days prior to screening:; Strong and moderate cytochrome P450 3A4 (CYP3A4) inhibitors, including but not limited to systemic (oral/IV) itraconazole, ketoconazole, fluconazole; erythromycin, clarithromycin, telithromycin; diltiazem, verapamil; aprepitant; cyclosporine; nefazodone; cimetidine; quinine; and HIV protease inhibitors; Strong and moderate CYP3A4 inducers, including but not limited to barbiturates (eg, phenobarbital and primidone), systemic (oral/IV) glucocorticoids, nevirapine, efavirenz, pioglitazone, carbamazepine, phenytoin, rifampin, rifabutin, and St. John's wort; Inhibitors of the BCRP (breast cancer resistance protein) transporter (eg, rifampicin); Drugs with narrow therapeutic margins (eg, digoxin, warfarin); Other Exclusions
- Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product
- Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 16 weeks after the last dose of investigational product
- Disease Related
- History of cluster headache or hemiplegic migraine headache
- Has a history of migraine aura with diplopia or impairment of levels of consciousness, hemiplegic migraine, or retinal migraine
- Has a chronic non-headache pain condition requiring daily pain medication
- Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
- History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; Medication related
- Greater than 50 years of age at migraine onset
- Inability to differentiate between migraine from other headaches
- The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
- Start of new preventive migraine treatment within the last two months
- Change in dosage of ongoing preventive migraine treatment within the last two months
- Female subjects of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test
- Evidence of current pregnancy or breastfeeding per subject self-report or medical records
- Subject has known sensitivity to any of the products or components to be administered during dosing
- Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (e.g, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.
A vizsgálat 2 csoportja
- AlmotriptanA vizsgált kezelés
12.5 mg almotriptan taken orally once
Kezelés: Almotriptan 12.5 Mg Oral Tablet
- UbrogepantMár használt kezelés, összehasonlításként
50 mg ubrogepant taken orally once
Kezelés: Ubrogepant 50Mg Tab
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).
- A regiszteradat frissítve
- 2025. május 31.